用于优化和个性化治疗儿童炎症性肠病中抗 TNF 药物的生物标志物
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.
作者信息
Salvador-Martín Sara, Melgarejo-Ortuño Alejandra, López-Fernández Luis A
机构信息
Servicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Spanish Clinical Research Network (SCReN), 28040 Madrid, Spain.
出版信息
Pharmaceutics. 2021 Oct 26;13(11):1786. doi: 10.3390/pharmaceutics13111786.
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota.
生物药物的使用改善了儿童炎症性肠病（IBD）的治疗效果。预测对生物药物的反应在IBD中非常有用，对于仍在身心发育阶段的儿童来说更是如此。尽管针对IBD儿童的研究较少，但特定的临床、生化和基因参数被认为可预测对生物药物的反应。在本综述中，我们介绍了目前关于儿童IBD生物治疗及可用反应生物标志物的证据。我们研究了人口统计学、临床特征、生物标志物（基因、基因组和细胞）以及微生物群。
Zotero 插件